STI Stock Trade Intelligence
ALA

AROVELLA THERAPEUTICS LIMITED

Health Care · ASX:ALA
$0.0490
0.00%
Market cap
$59M
Turnover
$30,467
Last price
$0.0490
Day change
0.00%
Announcements
14
Range, past year
Open 0.090 · Low 0.046 · Now 0.049 · High 0.130
Open ALA in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ALA momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
25/100
Wyckoff phase
Accumulation20d
Trend stage
Neutral
1 Day
+0.0%
1 Week
-5.8%
1 Month
-3.9%
1 Year
-45.6%
RSI
44
Avg daily range
5.0%

AROVELLA THERAPEUTICS LIMITED scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 20 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -25.4%
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
ALA appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ALA announcements

Recent price-sensitive releases.
  • 2026-11-04 Arovella Appoints CEO CEO/Managing Director - Appointment Resignation
  • 2026-10-27 First Patient Dosed with ALA-101 Progress Report
  • 2026-10-23 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-22 Arovella receives R&D tax rebate of $4.03 million Periodic Reports - Other | Company Administration - Other
  • 2026-10-07 Second Clinical Batch Released for Immediate Patient Use Progress Report
  • 2026-10-01 The path to first patient dosing Progress Report
  • 2026-09-07 Clinical manufacturing batch released, first site activated Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.